Shefali Agarwal
Shefali Agarwal

Dr. Shefali Agarwal is Epizyme’s Chief Medical Officer where she led the approval of Tazverik for Relapsed/Refractory Follicular Lymphoma and Epithelioid Sarcoma. She is currently also serving as a Board of Director for FATE Therapeutics and ITB-Med. Prior to joining the Epizyme, Shefali held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Shefali also held leadership positions at Curis and Tesaro. At Curis, she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At Tesaro, she led the NDA and EMA submissions for ZEJULA® (niraparib) in ovarian cancer. Shefali has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer.

In addition to receiving her medical degree, Shefali holds a Master of Public Health and a Master of Science in Business.

Tyler Curiel
Tyler Curiel

Tyler Curiel is a physician-scientist, Professor of Medicine and Microbiology, Immunology and Molecular Genetics at University of Texas Health San Antonio and holds the Daisy M. Skinner President’s Chair in Cancer Immunology Research. He received his BS summa cum laude from the University of Georgia, his MPH from Harvard and his MD from Duke. He completed internal medicine training at Yale, Infectious Disease training at Harvard/Massachusetts General Hospital and Medical Oncology training at the University of Colorado. He has significant NIH and other grant support and has served in many national and international leadership roles, including currently as a consulting editor for the Journal of Clinical Investigation. His lab investigates the immunopathogenic basis of human disease with an emphasis on novel strategies for cancer immunotherapy, concepts of which have been put into human clinical trials. Current work focuses on novel aspects of immune checkpoint blockade, pathogenic effects of regulatory T cells and on engineered cytokines.